Compare Eli Lilly And Co (LLY) vs Rigetti Computing Inc (RGTI) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

Rigetti Computing (RGTI) trades at $14.25, up 0.99% on the day, with a bearish technical signal despite bullish oscillators. The company shows significant financial challenges with a net income margin of -2,253.59% and negative cash flow from operations of $58.54M in 2025. Recent earnings have consistently beaten expectations, and analyst consensus remains strongly bullish with an average price target of $32.67, representing 129% upside potential from current levels.

While RGTI faces substantial execution risks in the pre-commercial quantum computing space, its government contracts and technological positioning offer long-term potential. Investors should weigh the company's speculative nature against analyst optimism and the emerging quantum computing market opportunity, with careful attention to cash burn and commercialization timelines.